DARIFENACIN Drug Patent Profile
✉ Email this page to a colleague
When do Darifenacin patents expire, and when can generic versions of Darifenacin launch?
Darifenacin is a drug marketed by Macleods Pharms Ltd, Alembic, Aurobindo Pharma, Cipla, Jubilant Generics, Ph Health, Puracap Labs Blu, Torrent, and Xiromed. and is included in nine NDAs.
The generic ingredient in DARIFENACIN is darifenacin hydrobromide. There is one drug master file entry for this compound. Nine suppliers are listed for this compound. Additional details are available on the darifenacin hydrobromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Darifenacin
A generic version of DARIFENACIN was approved as darifenacin hydrobromide by CIPLA on September 1st, 2016.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DARIFENACIN?
- What are the global sales for DARIFENACIN?
- What is Average Wholesale Price for DARIFENACIN?
Summary for DARIFENACIN
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 9 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 39 |
| Clinical Trials: | 22 |
| Patent Applications: | 3,648 |
| Drug Prices: | Drug price information for DARIFENACIN |
| What excipients (inactive ingredients) are in DARIFENACIN? | DARIFENACIN excipients list |
| DailyMed Link: | DARIFENACIN at DailyMed |
Recent Clinical Trials for DARIFENACIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Oliver Blanchard | PHASE2 |
| Université de Montréal | PHASE2 |
| Ain Shams University | PHASE1 |
Pharmacology for DARIFENACIN
| Drug Class | Cholinergic Muscarinic Antagonist |
| Mechanism of Action | Cholinergic Muscarinic Antagonists |
US Patents and Regulatory Information for DARIFENACIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Macleods Pharms Ltd | DARIFENACIN | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 207302-001 | Jul 28, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Xiromed | DARIFENACIN HYDROBROMIDE | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 209571-001 | Oct 22, 2019 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Cipla | DARIFENACIN HYDROBROMIDE | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 207664-001 | Sep 1, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for DARIFENACIN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| pharmaand GmbH | Emselex | darifenacin hydrobromide | EMEA/H/C/000554Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome. | Authorised | no | no | no | 2004-10-22 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
